Orion Infusions (DHA:ORIONINFU) EV-to-EBIT : 152.77 (As of Apr. 28, 2024)

View and export this data going back to . Start your Free Trial

What is Orion Infusions EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Orion Infusions's Enterprise Value is BDT12,473.6 Mil. Orion Infusions's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was BDT81.7 Mil. Therefore, Orion Infusions's EV-to-EBIT for today is 152.77.

The historical rank and industry rank for Orion Infusions's EV-to-EBIT or its related term are showing as below:

DHA:ORIONINFU' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.89 Med: 19.38 Max: 216.98
Current: 152.77

During the past 13 years, the highest EV-to-EBIT of Orion Infusions was 216.98. The lowest was 7.89. And the median was 19.38.

DHA:ORIONINFU's EV-to-EBIT is ranked worse than
96.86% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs DHA:ORIONINFU: 152.77

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Orion Infusions's Enterprise Value for the quarter that ended in Dec. 2023 was BDT7,681.0 Mil. Orion Infusions's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was BDT81.7 Mil. Orion Infusions's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 1.06%.

Orion Infusions EV-to-EBIT Historical Data

The historical data trend for Orion Infusions's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orion Infusions EV-to-EBIT Chart

Orion Infusions Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-EBIT

Get a 7-Day Free Trial

18.44

23.04

20.68

21.88

89.93

Orion Infusions Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															115.41	67.97	89.93	87.80	94.07

Competitive Comparison of Orion Infusions's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orion Infusions's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Orion Infusions's EV-to-EBIT falls into.

Orion Infusions EV-to-EBIT Calculation

Orion Infusions's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	12473.641	/	81.65
	=	152.77

Orion Infusions's current Enterprise Value is BDT12,473.6 Mil.
Orion Infusions's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT81.7 Mil.

Orion Infusions (DHA:ORIONINFU) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Orion Infusions's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	81.65	/	7680.96774
	=	1.06 %

Orion Infusions's Enterprise Value for the quarter that ended in Dec. 2023 was BDT7,681.0 Mil.
Orion Infusions's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT81.7 Mil.

Orion Infusions EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Orion Infusions's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Orion Infusions (DHA:ORIONINFU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orion Infusions Ltd (DHA:ORIONINFU) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tejgaon Industrial Area, No. 153-154, Dhaka, BGD, 1208

Website

https://www.orioninfusion.com

Orion Infusions Ltd is a pharmaceutical company. It produces various types of intravenous fluids, rehydration solutions, electrolyte solutions, antimicrobial products, and other pharmaceutical products in Bangladesh. The products of the company include Dextrolac, Dextropac, Dextrosal, Dianak, Electro dex, fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the company is also involved in activities related to cosmetics and toiletries, infrastructure development, real estate and construction, power, agro products, hospitality, textiles and garments, and aviation management sectors. Geographically, it operates in Bangladesh.

Orion Infusions (DHA:ORIONINFU) Headlines

No Headlines